Novel and Emerging Treatment Strategies for Acute Myeloid Leukemia

Presenter: Eunice S. Wang
Restricted access

Acute myeloid leukemia (AML) remains difficult and challenging to treat. Recognition that AML is a genomically heterogeneous disease has given rise to several new targeted therapies (eg, inhibitors of FLT3 and IDH1/2). Because the genomic landscape of AML evolves as the disease progresses, genomic testing is advised at diagnosis and at recurrence or relapse. In addition to targeted inhibitors, several emerging therapies directed at immune responses and p53 are on the horizon. Despite these advances, the 5-year overall survival rate for AML is 28.3%. The hope is that novel combinations and emerging strategies will move the survival bar higher for patients with AML in the near future.

Disclosures: Dr. Wang has disclosed that she has received consulting fees from AbbVie, Inc.; Astellas Pharma US, Inc.; Daiichi-Sankyo Co.; Jazz Pharmaceuticals Inc.; Kite Pharma; Celyad; Stemline; and Pfizer Inc.; and has received honoraria from Stemline and Pfizer Inc.

Correspondence: Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY 14263. Email: eunice.wang@roswellpark.org
  • 1.

    Röllig C, Kramer M, Schliemann C, Time from diagnosis to treatment does not affect outcome in intensively treated patients with newly diagnosed acute myeloid leukemia [abstract]. Blood 2019;134 (Suppl 1):Abstract 13.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Litzow MR, Ferrando AA. How I treat T-cell acute lymphoblastic leukemia in adults. Blood 2015;126:833841.

  • 3.

    Stone RM, Larson RA, Dohner H. Midostaurin in FLT-3 mutated acute myeloid leukemia. N Engl J Med 2017;377:1303.

  • 4.

    Cortes J, Khaled S. Martinelli G, . Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukemia (QuaNTUM-R): a multicenter, randomized, controlled, open-label, phase 3 trial. Lancet Oncol 2019;20:984997.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Perl AE, Marinelli G, Cortes JE, Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 2019;381:17281740.

  • 6.

    Esteve J, Schots R, Del Castillo TB, Multicenter, open-label 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in newly diagnosed FLT3-mutated acute myeloid leukemia patients ineligible for intensive induction chemotherapy: findings from the safety cohort [abstract]. Blood 2018;132(Suppl 1):Abstract 2738.

    • Search Google Scholar
    • Export Citation
  • 7.

    Stone RM, Mandrekar SJ, Sanford BL, Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017;377:454464.

  • 8.

    Ravandi F, Alattar ML, Grunwald MR, Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013;121:46554662.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Perl AE, Altman JK, Cortes J, Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol 2017;18:10611075.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Wang ES, Tallman MS, Stone RM, Low relapse rate in younger patients ≤ 60 years old with newly diagnosed FLT-3 mutated acute myeloid leukemia (AML) treated with crenolanib and cytarabine/anthracycline chemotherapy. Blood 2017;130:566.

    • Search Google Scholar
    • Export Citation
  • 11.

    DiNardo CD, Stein EM, deBotton S, Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 2018;378:23862398.

  • 12.

    Stein EM, DiNardo CD, Pollyea DA, . Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017;130:722731.

  • 13.

    Dinardo C, Jonas BA, Pullarkat V, A randomized double-blind placebo-controlled study of venetoclax with azacitidine vs azacitidine in treatment-naive patients with acute myeloid leukemia ineligible for intensive therapy: VIALE-A. Presented at the European Hematology Association (EHA) 25th Annual Congress; June 11–21, 2020; Frankfurt, Germany.

  • 14.

    Pratz KW, DiNardo CD, Arellano M, Outcomes after stem cell transplant in older adult patients with acute myeloid leukemia treated with venetoclax-based therapies [abstract]. Blood 2019;134(Suppl 1):Abstract 264.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Wei AH, Dohner H, Pocock C, The QUAZAR AML-001 maintenance trial: results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia in first remission [abstract]. Blood 2019;134(Suppl 2):Abstract LBA-3.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 298 298 298
PDF Downloads 89 89 89
EPUB Downloads 0 0 0